An early-stage biotechnology company was seeking to develop a global/regional strategy for the commercialisation of its Phase I compound ...
Over the past 25 years, PharmaVentures has conducted more that 700 assignments in support of the deal making process for our global clients. Our mandates and assignments span from strategy formulation through to successful M&A and licensing transactions. Our advisory services also include valuation of assets and expert witness services. Here we show a few recent project examples to illustrate the PharmaVentures expertise.
A major pharmaceutical company was seeking mid market growth products for emerging markets.
A European biotech needed to licence a clinical phase compound to treat a CNS disease
The Dow Chemical Company (Dow) engaged PharmaVentures to generate a transaction process and close a deal with the highest bidder for the opportunity
A US specialist drug delivery company needed urgently to get a valuation of a potential acquisition candidate company...
An established US biotechnology company and a US research institute faced a dispute over the commercial interpretation of a 10+ year-old licensing agreement...
An investment bank was looking to invest into a biotechnology company developing several novel products for orphan indications...
A large corporation planned to sell one of its key technology platforms and the compound originating from the Intellectual Property ...
A medium sized specialty pharma company was looking to expand its pipeline.
A mid sized life sciences manufacturing company with new cell lines sought the partnership of a global or several regional pharmaceutical companies.
A large diversified chemical company made a strategic decision to potentially divest one of its pharmaceutical related business units that lay outside its core strengths...
A Research & Development company was approaching the end of Phase II trials with a re-formulated compound...